The risk of cytomegalovirus recurrence after kidney transplantation

Primary CMV Infections Are Common in Kidney Transplant Recipients After 6 Months Valganciclovir Prophylaxis

(2010) I. Helanterä et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Effects of the Intensity of Immunosuppressive Therapy on Outcome of Treatment for CMV Disease in Organ Transplant Recipients

(2010) A. Åsberg et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Viral Impact on Long-term Kidney Graft Function

(2010) Ilkka Helanterä et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Evaluation of Cytomegalovirus (CMV)–Specific T Cell Immune Reconstitution Revealed That Baseline Antiviral Immunity, Prophylaxis, or Preemptive Therapy but not Antithymocyte Globulin Treatment Contribute to CMV‐Specific T Cell Reconstitution in Kidney Transplant Recipients

(2010) Davide Abate et al.   JOURNAL OF INFECTIOUS DISEASES

International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation

(2010) Camille N. Kotton et al.   TRANSPLANTATION

Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients

(2009) D. Kumar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients

(2009) A. Åsberg et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Delayed-Onset Primary Cytomegalovirus Disease and the Risk of Allograft Failure and Mortality after Kidney Transplantation

(2008) S. K. Arthurs et al.   CLINICAL INFECTIOUS DISEASES

Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients

(2008) I. Helantera et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION